Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...

A drug dealer who was jailed for six years has now been handed Hertfordshire's first slavery and trafficking prevention order ...

Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...

Evidence suggests that the justification for a 25 percent import tariff on Canadian goods and services does not hold up to ...

Nissan Altima was reported stolen at about 3:30 p.m. Jan. 25 from the parking lot of Speedway. Also, a North Royalton woman ...

Sen. Elizabeth Warren grilled Robert F. Kennedy Jr. over his plans to profit off of drug companies or lawsuits after being ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...